Mark is a pharmaceutical executive with more than 35 years of experience, covering all aspects of CMC (Chemistry, Manufacturing & Controls) research and development, from early drug development through commercial manufacturing.
Mark began his pharmaceutical career at The Upjohn Company (finally becoming Pfizer) as a process chemist working on API process development for clinical and commercial needs, eventually moving into the leadership of global, multi-site, chemical process R&D organizations with responsibilities for both laboratory and pilot plant facilities. From there he transitioned to portfolio management, providing broad technical, strategic and governance oversight for cross-functional CMC activities within a highly diversified portfolio of development projects.
Upon joining Johnson & Johnson (Janssen), he had responsibility for the API development group in the US and took over leadership of the global CMC Portfolio Management function with accountability for CMC activities across the entire small molecule development spectrum (pre-clinical to life cycle management; all therapeutic areas). His most recent role was in Janssen Supply Chain, leading End-to-End Strategy, where he helped orchestrate the end-to-end lifecycle management of commercial products, via improved strategies, oversight, and governance, with attention on delivering the best product possible.